Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer

Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer is a phase 2, interventional study registered as NCT07645118 by Dr. Te Vuong, with a registry enrolment figure of 10 participants, started 2026-07 and due to reach its primary completion in 2028-12. Interventions recorded: Nivolumab; HDRBET; Total Mesorectal Excision (TME). Conditions listed: Locally Advanced Rectal Cancer. Primary outcome: Pathologic complete response (pCR). Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma arising within 5 to 15 cm of the anal verge as measured by sigmoidoscopy or MRI". Sites: Canada. No results are recorded here; the registry entry is the source.